XOMA (XOMA) Competitors $24.04 -0.34 (-1.39%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XOMA vs. NVAX, OPK, GERN, MYGN, ZBIO, VSTM, RIGL, VNDA, EBS, and CDXSShould you be buying XOMA stock or one of its competitors? The main competitors of XOMA include Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Myriad Genetics (MYGN), Zenas Biopharma (ZBIO), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), Vanda Pharmaceuticals (VNDA), Emergent BioSolutions (EBS), and Codexis (CDXS). These companies are all part of the "biotechnology" industry. XOMA vs. Novavax OPKO Health Geron Myriad Genetics Zenas Biopharma Verastem Rigel Pharmaceuticals Vanda Pharmaceuticals Emergent BioSolutions Codexis XOMA (NASDAQ:XOMA) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, risk, analyst recommendations, media sentiment, earnings and profitability. Which has preferable earnings and valuation, XOMA or NVAX? XOMA has higher earnings, but lower revenue than Novavax. XOMA is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXOMA$10.22M28.12-$40.83M-$2.07-11.61Novavax$682.16M1.57-$545.06M-$1.33-5.02 Is XOMA or NVAX more profitable? Novavax has a net margin of -32.18% compared to XOMA's net margin of -151.34%. Novavax's return on equity of 0.00% beat XOMA's return on equity.Company Net Margins Return on Equity Return on Assets XOMA-151.34% -24.95% -9.64% Novavax -32.18%N/A -17.05% Do insiders and institutionals hold more shares of XOMA or NVAX? 95.9% of XOMA shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 7.2% of XOMA shares are owned by insiders. Comparatively, 1.0% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts prefer XOMA or NVAX? XOMA currently has a consensus target price of $69.50, suggesting a potential upside of 189.10%. Novavax has a consensus target price of $18.00, suggesting a potential upside of 169.87%. Given XOMA's stronger consensus rating and higher probable upside, research analysts clearly believe XOMA is more favorable than Novavax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XOMA 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Novavax 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Which has more volatility & risk, XOMA or NVAX? XOMA has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Novavax has a beta of 3.15, meaning that its share price is 215% more volatile than the S&P 500. Does the media favor XOMA or NVAX? In the previous week, Novavax had 31 more articles in the media than XOMA. MarketBeat recorded 32 mentions for Novavax and 1 mentions for XOMA. XOMA's average media sentiment score of 1.87 beat Novavax's score of 0.53 indicating that XOMA is being referred to more favorably in the media. Company Overall Sentiment XOMA Very Positive Novavax Positive Does the MarketBeat Community believe in XOMA or NVAX? Novavax received 409 more outperform votes than XOMA when rated by MarketBeat users. Likewise, 74.06% of users gave Novavax an outperform vote while only 65.58% of users gave XOMA an outperform vote. CompanyUnderperformOutperformXOMAOutperform Votes44265.58% Underperform Votes23234.42% NovavaxOutperform Votes85174.06% Underperform Votes29825.94% SummaryNovavax beats XOMA on 10 of the 18 factors compared between the two stocks. Get XOMA News Delivered to You Automatically Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XOMA vs. The Competition Export to ExcelMetricXOMAPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$287.35M$6.89B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-6.917.4422.4418.48Price / Sales28.12242.66394.66103.91Price / CashN/A65.8538.1834.62Price / Book3.116.516.774.25Net Income-$40.83M$143.21M$3.22B$248.23M7 Day Performance3.00%3.97%3.09%3.29%1 Month Performance18.25%0.37%-0.14%2.43%1 Year Performance-5.13%2.59%17.98%5.54% XOMA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XOMAXOMA4.0289 of 5 stars$24.04-1.4%$69.50+189.1%-5.1%$291.41M$10.22M-6.9110Upcoming EarningsPositive NewsNVAXNovavax3.6274 of 5 stars$6.01+0.2%$18.00+199.5%+54.0%$966.67M$682.16M-2.661,990OPKOPKO Health4.4856 of 5 stars$1.37-3.5%$2.75+100.7%+13.1%$920.02M$713.14M-7.214,200Earnings ReportShort Interest ↓News CoverageGERNGeron3.9973 of 5 stars$1.35+6.3%$5.75+325.9%-64.1%$859.83M$76.99M-4.2270Upcoming EarningsMYGNMyriad Genetics4.1007 of 5 stars$7.40-3.1%$20.61+178.5%-62.1%$682.07M$837.60M-5.692,600Upcoming EarningsHigh Trading VolumeZBIOZenas BiopharmaN/A$9.75+9.3%$40.00+310.3%N/A$407.54M$5M-2.75N/AGap DownVSTMVerastem3.1278 of 5 stars$6.21+8.2%$13.89+123.7%-24.9%$319.75M$10M-1.9550Upcoming EarningsAnalyst RevisionRIGLRigel Pharmaceuticals2.5977 of 5 stars$16.93+0.5%$36.80+117.4%+86.3%$302.49M$179.28M120.94160Upcoming EarningsPositive NewsGap DownVNDAVanda Pharmaceuticals4.1104 of 5 stars$4.29-0.9%$16.50+284.6%-5.3%$250.18M$198.77M-13.41290Upcoming EarningsShort Interest ↑Positive NewsEBSEmergent BioSolutions4.0215 of 5 stars$4.55-1.5%$14.33+215.0%+183.5%$247.23M$1.01B-1.112,420Upcoming EarningsGap DownCDXSCodexis3.5034 of 5 stars$2.13+0.9%$8.33+291.2%-21.0%$176.44M$59.35M-2.45250News CoveragePositive News Related Companies and Tools Related Companies Novavax Alternatives OPKO Health Alternatives Geron Alternatives Myriad Genetics Alternatives Zenas Biopharma Alternatives Verastem Alternatives Rigel Pharmaceuticals Alternatives Vanda Pharmaceuticals Alternatives Emergent BioSolutions Alternatives Codexis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XOMA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XOMA Stock Free XOMA Stock Alerts